Category: News

Internship program offers research experience, attracts bright minds to science

College students from across the U.S. are getting firsthand experience with the innovative work conducted at Southern Research in the latest generation of the nonprofit’s internship program.

Interns from Princeton University, Emory University, the University of Virginia, Birmingham-Southern College, the University of Alabama, and the University of Alabama at Birmingham (UAB) are among those who have participated and gained experience similar to that found in potential future careers.

Southern Research internship
Daniel Unger, a UAB senior majoring in chemistry and neuroscience, is working with a Southern Research team to develop a small molecule target for anti-HIV drugs.

The internship program within each department at Southern Research (SR) offers different opportunities. In general, most students do research for course credits. During the summer months, SR has paid interns which allows the students to gain additional experience outside of the classroom.

Southern Research has had various internship programs, but the newest program was initiated by Corinne Augelli-Szafran, Ph.D., director of the Chemistry Department in the Drug Discovery division.

“The intern program at SR is an excellent opportunity for the students to get hands-on experience in a laboratory. In addition to having the students exposed to a drug discovery environment, this program contributes to the Chemistry Department while reaching out to the community,” she said. “This type of program is good for everyone involved.”

In the Chemistry Department, a team of more than 25 chemists works on various research programs, including those involving treatments for Lou Gehrig’s disease (amyotrophic lateral sclerosis), Parkinson’s disease, Alzheimer’s disease, tuberculosis, kidney disease, HIV, and a wide range of cancers. The department is responsible for the preparation of potential new chemicals that will become drugs.

INITIATING A PROGRAM

Augelli-Szafran’s career in drug discovery research spans 30 years, with stints at Harvard Medical School, Parke-Davis, and Pfizer. At both of the big pharma firms, there were internship programs that drew students from neighboring universities into the workplace. At Harvard, she initiated a student internship program similar to the one she initiated at Southern Research.

When she came to SR, there was no such program in place at the time. What resulted in the Chemistry Department, is a program where students can earn course credits. Throughout the term, the students work with a mentor and do a presentation or write a research report at the end of the term.

Southern Research internship
Intern Katie Russell, a junior chemistry major at Birmingham-Southern College, is considering a career in drug discovery research.

“It’s been over a year now since we started the program, and we’ve had seven students come through in Chemistry,” she said. “They work in the lab, they do chemistry reactions, they make compounds, isolate them, purify them and characterize them – the same things a chemist would do.”

During their time in the program, if students are able to make a few compounds to be tested, it’s a major accomplishment, Augelli-Szafran added.

“It’s a great experience to learn how to do the chemistry. It’s just great exposure, and it can sometimes help the students decide what to do after undergraduate studies, whether to pursue further education or seek a job in a certain specialty.”

LAB EXPERIENCE

For the Drug Development division, the nine interns who worked there last summer served a great need, said Sarah Ziegler, Ph.D., biosafety program and compliance manager.

The group mainly worked on biosafety issues – keeping workers safe and regulatory compliance – in the division that is focused on taking pharmaceuticals and equipment to market and all that entails. The Drug Development division is responsible for a wide range of testing activities.

Out of the nine interns, Southern Research hired three for full-time positions after their internships were over.

“It was a way for us to get in help, but they also had a great perspective in a more innovative way,” Ziegler said. “They were mostly focused on biosafety and working with us on inventorying samples. They also did paperwork for us and lab cleanup. It was not necessarily the most fascinating work, but it was definitely very helpful for us.”

For the interns, the experience offered real-world work experience in a lab setting, she said.

“They actually had a lab they were in charge of, so they were understanding how to function in that arena. Their projects spanned the whole Southside campus. They interacted with people from Drug Discovery and Drug Development, and they met researchers in every lab.”

Part of the program involved a weekly lunch and learn where Ziegler invited interns from across the campus to hear from Southern Research scientists and other professionals.

“We had people talk about quality, human resources, Zika, influenza and more. It was really interesting, and I even learned things about my organization I didn’t know,” Ziegler said.

EXPLORING CAREERS

Southern Research internship
Abigail Holt, a sophomore chemistry major at Birmingham-Southern College, is interning at Southern Research.

Interns working in the Drug Discovery division say the experience they have gained is invaluable.

Birmingham-Southern College students Katie Russell and Abigail Holt are both interning at SR during the month of January to explore their future career and education paths.

Russell, a junior chemistry major, is learning organic synthesis techniques and how to analyze structure and purification data. She is an intern for postdoctoral researcher Shilpa Dutta, Ph.D., who is working on small molecule inhibitors for cancer therapeutics.

“I’m interested in the drug discovery career path, and I want to go to grad school,” Russell said. “I’ve done research work for one of my professors at Birmingham Southern, and I wanted to see how the process varies in an industry setting.”

Holt, a sophomore chemistry major, said she’s always been interested in pharmaceuticals and she’s trying to decide whether she wants to work as a researcher for a large firm.

“I think I’m really learning the most about day-to-day life and how professional chemists do their jobs instead of just being in a lab with a bunch of my classmates,” she said. “Even if I don’t end up becoming a researcher at a big pharmaceutical company, this internship has been really helpful in figuring out what I want to do. I’m glad I had the opportunity.”

UAB seniors Jaden Cowan and Daniel Unger are in the middle of longer internships. Cowan has been with Southern Research since last May, while Unger joined in August.

Southern Research internship
UAB senior Jaden Cowen, a chemistry major, is working on creating compounds for a potential anti-viral drug as part of his Southern Research internship.

Cowan, a chemistry major, initially did the internship for school credit, and he liked it so much he signed up for another semester to do his senior thesis. The thesis is on the work he’s done so far, which is creating compounds that could be used in an anti-viral drug.

His ultimate goal is to become a research scientist. During his time at SR, he has set up experiments, monitored those, run tests on the compounds, and analyzed the results.

“Since I’ve been here, I’ve decided I’m going to try to obtain a Ph.D. in chemistry, and all these skills I’ve learned so far during this internship are going to be directly used in graduate school,” Cowan said. “This is good experience working in a professional lab alongside professional researchers. They’re prepping me so I can be independent and work in a lab by myself later on.”

Unger, a chemistry and neuroscience major, joined Southern Research after reconsidering his career plans.

“I added my chemistry major in the spring of last year, after I decided to look into career options other than medicine. I came the realization that I really enjoyed teaching,” he said. “So I decided to get a Ph.D. in chemistry, and I needed hands-on experience in the lab.”

Currently, Unger is working with a team on a project to develop a small molecule inhibitor as an anti-HIV therapy, a compound that essentially stops the virus from being able to replicate itself.

He sets up reactions on his own, as guided by his research mentor, and he follows the reactions, checking to see when they are completed. He also isolates and characterizes products from various reactions.

“It’s absolutely been beneficial, and I feel I’ve learned a lot. I have a much better grasp on what’s involved in doing the work as I prepare for grad school,” Unger said.

ATTRACTING TALENT

Dr. Bo Xu, MD, Ph.D., distinguished fellow and chair of the Oncology Department, said the internship program helps Southern Research attract more talented people to join the nonprofit.

Xu notes SR’s long and storied history when it comes to cancer research, which dates to the 1940s and includes more than $90 million in grant funding from the National Institutes of Health alone.

“It is part of our mission that we want to attract more talented people to join us, to be future scientists,” he said. “We want to see them get involved and engaged in the early stages of their career and training.”

Interns in the Oncology Department typically are assigned a small project, as well as a mentor who provides hands-on training. They’re taught how to design an experiment, analyze the data, write a report and present it to the entire department at the end of the term.

The subject matter the interns are studying is the cutting edge of cancer research, Xu said.

For example, this year a student from UVA shadowed a Southern Research scientist and learned about immunology/oncology research, specifically how to culture lymphocytes and how to design experiments for potential treatments.

“Basically we are having more young people come and learn and understand what science is, what cancer research is and how cancer research can help people,” he said.

Robert R. Meyer Foundation gift boosts Drug Discovery efforts

Birmingham’s Robert R. Meyer Foundation is supporting Southern Research’s Drug Discovery program with a $500,000 gift that aims to accelerate efforts to find new treatments for unmet medical conditions and rare and neglected diseases.

The contribution renews close ties between the Birmingham-based non-profit research organization and a charitable trust that became an important backer of its scientific work more than 60 years ago.

Southern Research has earned a solid reputation in drug discovery, with seven FDA-approved anticancer drugs, a number that ranks it among the most prolific in the field. In addition, Southern Research’s labs have screened many other potential medicines, and its researchers have developed a robust pipeline of promising therapeutics.

Southern Research Meyer Foundation
John Meyer, front row, second from right, stands for a photo at the dedication of Kettering-Meyer Lab II in 1958. His wife is next to him, and daughter Nancy behind him.

“The Robert R. Meyer Foundation’s longstanding support of Southern Research has been fruitful, contributing to many discoveries made by the organization’s scientists that have improved the lives of people battling cancer and other serious diseases,” said Beverly Baker, an Advisory Committee member for the foundation.

“The foundation’s leadership is confident that this gift will facilitate additional insights that lead the way to new treatments,” Baker added.

EARLY SUPPORT

The Meyer Foundation has supported Southern Research since 1953, when it provided $100,000 to match funding from the Charles F. Kettering Foundation for the construction of the Kettering-Meyer Laboratory. The Meyer Foundation made another significant contribution in 1957 to facilitate construction of a second Kettering-Meyer Lab.

In addition, the foundation has supported Southern Research’s cancer programs with other donations over the years.

“Significant gifts from the Robert R. Meyer Foundation in the 1950s enabled Southern Research to make important advances in drug discovery and have contributed to the impact our research and drugs have made on patients around the world,” said Art Tipton, Ph.D., president and CEO of Southern Research.

“The foundation’s latest gift will allow us to continue to explore important scientific breakthroughs that are high-risk, high-reward endeavors, rarely funded through government grants,” Tipton added. “This is the kind of research that results in the discovery of new drugs.”

Southern Research’s Drug Discovery division focuses on identifying novel treatments for serious conditions such as cancer, Parkinson’s disease, Alzheimer’s disease, diabetes, and viral and bacterial infections.

The division works as a partner of the National Cancer Institute, the National Institute of Allergy and Infectious Diseases, and the National Institute of Drug Abuse, among others. It also collaborates with the Cystic Fibrosis Foundation, the Muscular Dystrophy Foundation, and other non-profit organizations and research institutions.

“Southern Research has the unparalleled capacity to investigate a wide range of potential treatments for complicated conditions,” said Mark J. Suto, Ph.D., vice president of the Drug Discovery division.

“Our innovative research programs and unique technological capabilities position the scientists at Southern Research to investigate possibilities and achieve meaningful outcomes.”

IMPORTANT CONTRIBUTIONS

The Robert R. Meyer Foundation was formed in 1942, just one year after the founding of Southern Research. Over the years, it has contributed more than $65 million to hundreds of charitable organizations.

Robert Meyer was a prosperous hotel operator with properties in Birmingham; Baltimore; Jacksonville, Florida; Nashville and Knoxville, Tennessee; and Raleigh, North Carolina. He served on the boards of the Waldorf Astoria and Governor Clinton hotels in New York City, as well as local enterprises such as DeBardeleben Coal and Woodward Iron.

He also served on Southern Research’s board of directors in 1946, one year before his death. His son, John Meyer, became a member of the board the next year, serving until 1970.

John Meyer was optimistic that cancer research would unravel the mysteries of the deadly disease and yield new treatments. At the dedication ceremony for the Kettering-Meyer lab on Dec. 17, 1953, John Meyer introduced his oldest daughter, Jane, to those attending the event.

“It seems particularly appropriate that youngsters of Janie’s age group should play a part here since their generation undoubtedly will be among the largest beneficiaries of current cancer research,” John Meyer said. “It is not only possible, but altogether probable, that by the time this young lady reaches maturity, the battle with cancer will have been won.”

While the struggle has not yet been won, the Meyer Foundation’s latest gift will help Southern Research continue the fight through the search for new medicines.

Southern Research hires Michael Catalano as VP and general counsel

michael-cantalano Southern Research announced today the hiring of Michael Catalano as vice president and general counsel. In this role, he will lead both the Intellectual Property and Contracts teams in working closely with all four Southern Research divisions to identify areas of IP growth and to cultivate external and internal operations. For over 20 years, Catalano has served in leadership roles across diverse industries, such as commercial and corporate law, healthcare, and entertainment, where he has gained expertise in business development, acquisitions, operations, and IP.

“Southern Research is pleased to welcome Michael and his remarkable legal and financial expertise,” said Southern Research President and CEO Art Tipton, Ph.D. “We look forward to the impact his wide-ranging experience will have across our diverse portfolio of projects.”

Prior to Southern Research, Catalano was general counsel and privacy officer at Influence Health, where he focused on transactions, strategic initiatives, and corporate compliance. His experience previous to Influence Health includes: chief operating officer, corporate secretary and general counsel for Nashville, Tennessee-based SilverStaff Inc., a privately-funded healthcare development company that launched and operated a disease management company; vice president of finance for Caesars Entertainment Inc.; and senior development counsel for pharmacy health care provider CVS Caremark. Catalano began his career as an associate with Birmingham-based law firm Sirote & Permutt P.C., where he practiced in commercial litigation and corporate transactions.

“I am honored to be a part of the Southern Research team as it enters an exciting period of growth. It is a rare opportunity to be a part of a team that is working to solve the world’s hardest problems and actually delivering on that promise,” said Catalano. “I am humbled by the intellect and experience that surrounds me here, and I have a lot to learn from this incredible team. My experience across several highly-regulated industries will allow me to bring a fresh set of eyes to the opportunities in this organization, and I welcome the challenges ahead.    “

Catalano earned a J.D. from Samford University’s Cumberland School of Law, and he holds an MBA in finance from Vanderbilt University’s Owen Graduate School of Management. He earned his Bachelor of the Arts degree from DePauw University.

Southern Research names new members to board of directors

Southern Research announced today that C. Ray Hayes, chancellor of the University of Alabama System, and Nancy E. Dunlap, M.D., Ph.D., an accomplished health care administrator and professional, have joined the non-profit organization’s board of directors.

Both Hayes and Dr. Dunlap have had distinguished careers in leadership roles at organizations committed to advancing science and increasing knowledge, which aligns with Birmingham-based Southern Research’s overall mission.

Hayes became the chancellor of The University of Alabama System on Sept. 1, 2016, placing him in charge of a three-campus system with more than 65,000 students, 37,000 employees, and an annual budget approaching $6 billion. Prior to that, he served as the executive vice chancellor and chief operating officer, overseeing the system’s budgeting and financial affairs.

Hayes’ professional career spans three decades of senior administrative leadership at The University of Alabama System, Mississippi State University and Texas A&M University.

“Southern Research, having recently celebrated its 75th anniversary, has a rich history in Alabama and is currently at the forefront of exciting scientific discovery that is saving lives and helping shape our state’s profile as a global research center,” Hayes said. “As a member of the board of directors, it will be a privilege to work with Dr. Art Tipton and his team to support their efforts.  I appreciate this opportunity.”

Dr. Dunlap, a pulmonologist, has had a varied career of more than 30 years of academic clinical practice and teaching, basic investigative research, clinical trials experience, health information technology implementation, quality improvement, and healthcare administration.

Dr. Nancy Dunlap is professor emerita and scholar at UAB's Lister Hill Center for Health Policy.
Dr. Nancy Dunlap

She has served in high-ranking roles at the University of Virginia and the University of Alabama at Birmingham (UAB), where she is currently professor emerita and scholar at the Lister Hill Center for Health Policy. She also served two stints as physician-in-residence for the National Governors Association’s Center for Best Practices and spent one year as the Robert Wood Johnson Health Policy Fellow for the U.S. House of Representatives’ Committee on Energy and Commerce.

At the University of Virginia, Dr. Dunlap served as dean of the School of Medicine, making her responsible for educational, clinical, and research programs, and later as a professor of Medicine, Nursing and Public Health Services. At UAB, she has held numerous appointments with high levels of responsibility.

“Southern Research has an impressive record of accomplishment in many fields, and its talented scientists and engineers consistently make important contributions both in the laboratory and the real world,” Dr. Dunlap said. “As a member of the organization’s board of directors, I am eager to see this tradition of innovation and discovery continue well into the future.”

“Southern Research has been fortunate to have such an engaged and strong board of directors. I am thrilled that Ray and Nancy will be part of that going forward, and I tremendously look forward to their insight and advice,” said Southern Research President and CEO Arthur J. Tipton.

Southern Research’s board of directors is made up of 10 members, each serving a three-year term.

Current members are Ray L. Watts, M.D., (chair), president of UAB; G. Allen Bolton Jr. (treasurer), vice president for financial affairs and administration at UAB; Mark Crosswhite, president and CEO of Alabama Power Co.; Fournier J. Gale III, senior executive vice president of Regions Financial Corp.; Daniel O. Hayden, independent management consultant and retired senior vice president and general manager, Pharmaceuticals Division, Genzyme Corp., now a Sanofi company; Gene Ruffner Page Jr., president of McWane Inc.; Charles K. Porter, executive vice president, Porter White & Co.; and N. Lee S. Price, Maj. Gen., U.S. Army (retired) and president, Price Solutions LLC.

Drug discovery scientist Mark Suto named to National Academy of Inventors

Mark J. Suto, Ph.D., vice president of Drug Discovery at Southern Research, has been named a Fellow of the National Academy of Inventors (NAI) in recognition of his wide-ranging contributions to pharmaceutical research and drug discovery efforts.

During a career spanning more than 34 years, Suto has made significant advances in many clinical areas of the drug discovery process, including medicinal and computational chemistry, as well as lead optimization.

Southern Research Suto
Mark Suto directs the Drug Discovery division at Southern Research.

He holds 45 patents in the field of chemistry and drug discovery, along with numerous foreign equivalents. Suto’s patents focusing on ion channels in cells were acquired by pharmaceutical giant Pfizer. Several compounds from these patents are now in clinical trials.

“Throughout his career, Suto has fostered an international scientific reputation through high-impact publications, service as reviewer and editor for multiple prestigious scientific journals, 45 patents, and research presentations and lectures reflecting his broad expertise across the globe,” said Art Tipton, Ph.D., president and CEO of Southern Research.

CLASS OF 2016

Suto is the second NAI Fellow from Southern Research, joining Tipton, who was selected in 2013. Suto was among 175 leaders of academic invention named to NAI Fellow status today, according to an announcement.

NAI is a Tampa, Florida-based organization that recognizes inventors with patents issued from the U.S. Patent and Trademark Office and seeks to enhance the visibility of academic technology and innovation.

Each year, the NAI selects academic researchers who have demonstrated a spirit of innovation by creating inventions that lead to tangible improvements to quality of life and the welfare of society.

With the election of the 2016 class, there are now 757 NAI Fellows, representing 229 research universities and governmental and non-profit research institutes. The 2016 Fellows are named inventors on 5,437 issued U.S. patents, bringing the collective total held by all NAI Fellows to more than 26,000.

Suto and other new NAI Fellows will be inducted during a ceremony on April 6, 2017, at the John F. Kennedy Presidential Library and Museum in Boston.

“It is exciting to see the NAI Fellows Program continue to grow and honor the world’s most impactful academic inventors each year,” NAI President Paul R. Sanberg said in today’s announcement. “The 2016 Fellows exude innovative excellence and we feel truly privileged to welcome them to the Academy and recognize their remarkable contributions to discovery and invention.”

TARGETING THERAPIES

Suto joined Southern Research as vice president of Drug Discovery in 2011. At the Birmingham-based non-profit organization, he and his team focus on target identification and lead discovery and optimization of novel therapies for cancer, infectious diseases, and neurological diseases and disorders.

He serves as principal investigator on several NIH-funded programs, including the National Cancer Institute’s Chemical Biological Consortium, whose strategic mission is to accelerate the discovery and development of innovative cancer therapies.

Before joining Southern Research, Suto led major scientific and operational projects as an executive at pharmaceutical start-up companies. He also held positions of increasing responsibility in the chemistry department at Parke-Davis Pharmaceutical Research in Michigan.

NRG COSIA Carbon XPRIZE taps Southern Research for global independent validation of carbon dioxide utilization technologies

NRG COSIA Carbon XPRIZE and Southern Research’s Energy & Environment (E&E) division today announced a partnership to help with the independent validation of competing technologies in the NRG COSIA Carbon XPRIZE –- a $20 million global competition that incents innovators to transform how the world approaches CO2 mitigation with the development of groundbreaking technologies that convert carbon dioxide emissions into valuable products.

Southern Research will serve as an independent, unbiased technical evaluator tasked with assessing performance of the competing technologies. In this role, technologists from the organization’s E&E division will visit each of the competing teams and validate each technology’s performance based on the two primary scoring criteria of the competition: how much CO2 they are able to convert, and the net value of products created with the carbon.

Southern Research XPRIZE
Santosh Gangwal, right, and Tim Hansen of Southern Research’s E&E division discuss research findings.

“Southern Research represents the type of rigor, independence and experience we need in order to properly test the broad diversity of new carbon conversion technologies in this competition,” said NRG COSIA Carbon XPRIZE Director of Technical Operations Marcius Extavour.

“XPRIZE is an innovation engine that tries to catalyze breakthrough technologies that can address our collective grand challenges,” he added. “Climate change and carbon emissions are in that category, and we know that Southern Research has been at the forefront of technology and standards in this field for decades. We’re excited to bring their expertise to bear.”

“Our team of scientists and engineers have experience in deploying and testing new renewable energy and environmental management technologies in the field. That real world experience, combined with process modeling and analytical capabilities, gives us the ability to judge which technologies are more likely to succeed when commercialized,” said Bill Grieco, vice president of Southern Research’s E&E division.

HISTORICAL EXPERTISE

For over 40 years, the division has been testing, developing and licensing technologies designed to help energy producers and industry manage their environmental footprint. Southern Research specializes in controlling the environmental footprint of processes for energy generation and distribution, water treatment and reuse, and chemicals and fuel manufacturing.

Of particular relevance to the NRG COSIA Carbon XPRIZE, E&E manages a task force specifically for independent performance validation and demonstration of energy and related sustainable technologies. This team also strives to predict the economic and life cycle impacts of emerging technologies with techno-economic analyses (TEA) and life cycle assessments (LCA).

This team has also been deeply involved in the development of ISO 14034, an international standard to define how the performance of environmental technologies are evaluated.

Southern Research XPRIZE
Santosh Gangwal

“The vast majority of energy consumed in the world will continue to be produced from fossil fuels such as oil, natural gas and coal for the foreseeable future,” said Santosh Gangwal, director of business development, Southern Research’s E&E division. “When combusted, fossil fuels expel CO2 into the atmosphere, which could contribute to changes in the earth’s climate.

“While there can only be one winner for the Carbon XPRIZE competition, this is important work, and we strongly encourage all competing teams to continue developing these transformative technologies,” he said. “The independent validation provided by Southern Research and XPRIZE is a valuable benefit to all teams.”

XPRIZE competitions assess the contestants’ innovations in three stages: a submission round, a laboratory testing round, and a demonstration round where the contestants’ technologies are examined under real world conditions. The 4½-year NRG COSIA Carbon XPRIZE competition will include all three rounds across two tracks — one focused on testing technologies at a coal plant and another that focuses on testing technologies at a natural gas power plant. Each track will operate as a separate competition on the same timeline.

Southern Research will lend its expertise to working closely with the Carbon XPRIZE and its competing teams to help scale these breakthrough technologies in the second stage of the competition in real and tangible ways.

 

 

 

Southern Research celebrates 2016 Excellence Award winners

Southern Research honored winners of its employee Excellence Awards program at a program last week showcasing work across the organization this year that exemplified the non-profit’s core values.

The work of the winners supported Southern Research in wide-ranging ways in 2016, from advancing science and technology to making the organization a safer, more efficient, more productive workplace. In all cases, the winners showed a deep commitment to serving Southern Research, its sponsors and their co-workers.

“Southern Research was founded 75 years ago, and it remains vital today because of the capabilities and dedicate of our talented team,” said Art Tipton, Ph.D., president and CEO.

“Our employees come to work every day focusing on making the world a better place in a broad range of technical areas, I’m confident that the organization will continue to celebrate innovation and accomplishment for many generations to come,” he added.

President and CEO Art Tipton, right, presents Tim Ferguson with the President's Award.
President and CEO Art Tipton, right, presents Tim Ferguson with the President’s Award.

At the program, Tipton presented the President’s Award to Tim Ferguson, the leader of the Engineering Division’s Mechanics Department who has exceeded customer expectations with excellent technical solutions for more than a decade.

Tipton commented on Ferguson’s performance leading a profitable, growing department to high standards and demonstrating year-over-year financial growth independent of fluctuations in government or commercial funding.

“I am thrilled to present this award this year to someone nearer the beginning than the end of their career, and I look forward to Tim continuing to be an example of excellence to the entire Southern Research family,” he added.

Receiving Excellence Awards for their work in 2016 were:

The QVOA Team: A group of six scientists worked for a year to validate and standardize the Quantitative Viral Outgrowth Assay (QVOA), an important component of a major contract with the Department of AIDS at the National Institutes of Health, and focused on a cure for HIV/AIDS. The team is Marie Mankowski, Christine Raney, Jiayi Wei, Rebecca Bernbaum, Haley Madeira, and Yury Kuzmichev.

Amy Sands: Playing a dual role as project coordinator and technical supervisor, Sands has been in the lab part time while also acting as a technical mentor to junior biologists and supporting the study directors.

Carrie Evans: As divisional project manager, Evans has developed processes and procedures to more efficiently track progress on a range of technical programs. She also has acted as an intermediary with the Finance Department, a key role with new budgeting and forecasting processes coming online, and one that allows the organization’s key scientists to concentrate more fully on scientific progress.

Helga Alexander: Responsible for Southern Research’s ISO program, Alexander prepared the organization for more rigorous ISO standards through a more robust internal audit process and ensured the implementation of identified process improvements. Southern Research’s recent ISO renewal audit produced no findings.

James Hawbaker: Hawbaker developed an optical strain system based on sophisticated image analysis that enables making non-contact strain measurements at extremely high temperatures.

 Kenny Deerman: Since February, Deerman has provided cross-divisional support as a fill-in Selective Catalytic Reduction catalyst sample prep technician for the Energy & Environment (E&E) division, displaying workmanship, quality and productivity in the role.

Dave Stewart: On top of his normal workload, Stewart stepped up to help E&E carry out a successful move from the Southside Birmingham campus to the Oxmoor location in 2016.

Curtis Thompson: Tasked with preparing a proposal for funding from the Department of Energy for a joint project with UAB, Thompson pursued the right collaborative relationships and completed the process flawlessly. The $150,000 DOE award is to develop a continuous water quality monitor.

Amit Goyal: Leading a program in sustainable chemistry and catalyst development in E&E’s Clean Technology Development group in Durham, Goyal won E&E’s single largest funding award from the Department of Energy to develop chemical products from biomass sugar. He also filed six invention disclosures and three patent applications in 2016.

Javier Campos-Gomez: With a vibrant research program in acute and chronic infectious diseases, Campos-Gomez has been awarded funding by both the Center for Clinical and Translational Science (CCTS) and and the Alabama Drug Discovery Alliance. In addition, the far-reaching implications of his discoveries have been published in a top-tier scientific journal.

Brynne MacCann: With Southern Research marking its 75th anniversary in 2016, MacCann was instrumental in the launch of a new, multi-faceted philanthropic outreach program.

Jason Quick: A technician adaptable to changes in test plans and customer and engineer requirements, Quick has been able to surpass expectations.

Kim Blatz: Responsible for increasing a culture of safety and environmental awareness at the E&E Durham facility, Blatz clearly demonstrated a core value of the organization.

Curtis Champion: A multi-tasker in E&E’s Facilities Group with a busy schedule, Champion sets an example for the organization of how to communicate with internal customers.

Carlton Green: Responsible for facilities and maintenance at the E&E Durham facility, Green implemented numerous site-wide improvements including a 5 S system to improve workplace efficiency and safety, and the installation of energy efficient lighting for utility savings.

Researchers find clue on how to block biofilm shields of bacterial infections

An investigation by Southern Research biologists reveals for the first time that fatty acids known as oxylipins play a critical role in the formation of the biofilm shield that protects disease-causing bacteria from antibiotics.

A paper explaining this process, “Oxylipins produced by Pseudomonas aeruginosa promote biofilm formation and virulence,” appeared Dec. 8 in Nature Communications, a peer-reviewed scientific journal. Authors are Javier Campos-Gomez, Ph.D., research biologist in Southern Research’s Drug Discovery Division, and Eriel Martinez, Ph.D., a researcher in the Campos-Gomez Laboratory.

Southern Research Campos-Gomez lab
Eriel Martinez, left, and Javier Campos-Gomez at work in the laboratory.

The findings have significant implications for understanding the formation of biofilms of bacterial pathogens with multiple antibiotic resistance mechanisms that are responsible for opportunistic infections in immunocompromised individuals and others, Campos-Gomez said.

“When the bacterium produces the oxylipins, the biofilm is stronger,” he said. “When you remove the capacity of the bacteria to produce oxylipin, it’s unable to make the biofilm, and the host organism is able to better fight off the infection.”

BACTERIAL COLONIES

Oxylipins are common in nature, and have been studied extensively in animals, plants, algae, and fungi, but the biological functions of these oxygenated fatty acids in bacteria have largely remained unexplained.

Campos-Gomez and Martinez studied P. aeruginosa – an antibiotic-resistant bacterium that causes disease in plants and animals – to better understand how oxylipins act to promote the organization of bacterial colonies into a more complex organization known as biofilm, where the bacteria are embedded inside a matrix that protect them from antibiotics.

Their findings show that oxylipin production essentially changes the bacteria from a free-swimming state to what amounts to a fixed state, allowing for the formation of a colony.

The researchers’ in vitro and in vivo (Drosophila flies) studies indicated that this step increased the ability of P. aeruginosa to form biofilms. They also demonstrated that the oxylipins produced by the bacterium promoted virulence in the flies and in lettuce leaves.

“We think oxylipins are signaling molecules that probably trigger other known or unknown pathways responsible for the biofilm production,” Campos-Gomez said.

PATHWAY FOR TREATMENTS

Oxylipin’s central role in promoting bacterial organization and biofilm formation may offer a promising opportunity for new medicines or therapies. The development of an oxylipin blocker could make a formerly antibiotic-resistant bacterial infection once again treatable, Campos-Gomez said.

As a next phase in their research, Campos-Gomez and Martinez plan to use Southern Research’s state-of-the-art high throughput screening facilities and large compound collection to identify agents that could act to block the production of oxylipin in bacteria.

In essence, understanding how bacteria rely on oxylipin production to create biofilms creates a new pathway for treatments that could save lives.

“It’s very difficult to treat these infections because of the biofilm, which acts as a shield against antibiotics and the host defenses, making it impossible for the infected host’s immune system to clear the bacteria from the body,” Campos-Gomez said.

“The host is unable to handle the infection, and it’s often fatal.”

Southern Research influenza program targets broad-spectrum antiviral against flu threats

Southern Research scientists are targeting a specific protein complex in influenza in the search for a new drug to counter a virus that infects more than 3 million people each year and has a history of catastrophic pandemics.

“Influenza remains a big killer,” said Mohammad F. Saeed, Ph.D., a research scientist in Drug Discovery who is directing Southern Research’s program to develop a treatment against the virus.

Southern Research influenza
Southern Research scientists are seeking to develop a drug that’s effective against several influenza strains.

Influenza is blamed in the deaths of between 250,000 and 500,000 people across the globe each year, according to the World Health Organization. In the U.S., annual flu deaths range from around 3,000 to just under 50,000, the Centers for Disease Control and Prevention (CDC) estimates.

Vaccines offer protection against seasonal influenza, but Saeed says there are many reasons to pursue the development of a broad-spectrum antiviral that’s effective against several strains of the virus. That’s the goal of his work, which is funded through a National Institutes of Health grant.

“Let’s say we have a pandemic like we had in 2009 with swine flu — the vaccine wouldn’t work against that because that is a different variety of influenza,” Saeed said. “Every now and then, you see a different strain of influenza entering human population and becoming more prevalent globally because the existing vaccines are ineffective against the new strain. To generate a vaccine for the new variety, it would take six to nine months, or a year.”

Southern Research influenza
In 2009, a pandemic of H1N1 influenza, or swine flu, killed 284,000 people worldwide.

Scientists say the 2009 swine flu was a new form of the H1N1 influenza virus that rapidly spread around the globe much like the 1918 pandemic that killed as many as 100 million people, most of them young, healthy adults. The CDC put the death toll from the 2009 swine flu pandemic at 284,000 worldwide.

BIRD FLU DANGERS

In addition, the threat posed by avian influenza underscores the need to develop an effective antiviral treatment as a protective measure, Saeed said.

While bird flu doesn’t typically infect humans, there are no vaccines for these influenza strains. Plus, the H5N1 avian influenza virus has shown a very high mortality rate in cases of human transmission.

“Normally these viruses don’t jump species, from birds to humans, but our biggest concern is what if they acquire mutations in nature so that they can more frequently infect humans?” Saeed said. “That would become a big problem, because these viruses are more pathogenic than the influenza virus we see in human populations.”

With no vaccine available, a highly pathogenic mutated avian influenza virus would likely kill people in greater numbers, and even those otherwise healthy individuals who usually can fight off infection with the seasonal influenza viruses.

“That’s our concern, and that’s why we want to have drugs against influenza viruses,” Saeed said. “In an outbreak, if we don’t have time to get a vaccine in place, we’ll at least have drugs for people who are already infected to save their lives.”

TARGET: POLYMERASE

Researchers have developed drugs that are useful against influenza, but the virus can develop resistance.

For example, amantadine, which disrupts the virus release from infected cells in Type A influenza, and thereby prevents its spread, is no longer recommended for treatment of influenza in the U.S. because of resistance, Saeed said. The CDC says sporadic resistance has been spotted with oseltamivir, the most widely used antiviral flu medication.

“These viruses mutate all the time. That’s the way they work,” Saeed said. “For us, the important point is to target some protein in the virus that doesn’t mutate as frequently.”

The Southern Research team is targeting a protein complex in influenza viruses called polymerase, which plays a central role in viral replication. In recent years, scientists have made breakthroughs in revealing the structure of this protein complex, opening opportunities for sophisticated drug design techniques.

Additionally, the polymerase protein complex is relatively consistent across several influenza virus subtypes, meaning a drug that works against one form of the flu could work against many others.

“Without those proteins, the virus cannot replicate,” Saeed said. “If we can inhibit those proteins, we can stop the virus in its tracks.”

Scientists also believe that because this set of three proteins performs such an essential function to the virus, mutations within the complex should be rare. That means the likelihood of the virus developing resistance to a polymerase-targeted drug should be low.

DRUG DISCOVERY

Southern Research, whose antiviral work started in the 1950s, is well positioned to make advances against influenza.

High Throughput Screening on Zika
Scientist working with assays in Southern Research’s High Throughput Screening lab.

Scientists at the organization’s infectious disease labs in Birmingham and Frederick, Maryland, have studied a wide range of viral threats, from polio and HIV/AIDS to dengue and Zika. It has a vast library of compounds to examine for activity against influenza, and a state-of-the-art high throughput screening facility with dedicated experts to perform that operation at scale.

“We have a compound collect with approximately 500,000 samples available for screening against influenza viruses,” Saeed said. “We start with the seasonal and pandemic strains. Then we’ll test the compounds that show activity against the avian viruses.”

So far, the Southern Research team has tested about 200,000 compounds in the collection, turning up close to 900 “hits,” or agents that showed activity against influenza, Saeed said. Further screening determines whether the agents are acting against the targeted protein complex.

As part of the drug discovery process, Southern Research chemists assist by designing new molecules from the active agents that are better tolerated in the human body and consistently reach the target area in the virus.

“There are multiple subtypes of influenza viruses, so our goal in this program is to find small-molecule drugs that could potentially have activity against many different subtypes,” Saeed said.

“Influenza pandemics have killed millions of people, and in the case of an outbreak of a highly pathogenic influenza virus, there just won’t be time to develop a vaccine,” he added. “We need a drug against this threat.”

Daniel Foundation supports Southern Research with $225,000 gift

The Daniel Foundation of Alabama is supporting Southern Research’s economic development activities with a $225,000 grant, building on the longstanding ties between the two Birmingham organizations.

Southern Research Daniel Foundation
The Daniel Foundation gift will provide a boost to research with an economic development component.

The gift will provide a boost to Southern Research programs and projects that raise the profile of Birmingham and Alabama, enhance their attractiveness for outside investment, and increase the state’s competitiveness in the global economy.

“The Daniel Foundation Trustees realize the unique role Southern Research plays in the economic fabric of our region,” said Charles W. Daniel, the foundation’s chairman. “Their research capacity reaches far beyond our region and introduces new drugs, technology, and methodology to the world.

“The board was pleased to support these efforts in honor of the 75th anniversary of Southern Research,” he added.

BENEFACTORS

Southern Research’s bonds with the Daniel family stretch back to the early days of the research organization founded in Alabama in 1941.

Charles E. Daniel, a co-founder of the Daniel International Construction Co., served on Southern Research’s board from 1946 to 1959. His brother, R. Hugh Daniel, another co-founder of the family firm, was a board member between 1964 and 1970.

The Daniel construction firm erected several buildings on Southern Research’s campus on Birmingham’s Southside. The Daniel Laboratory on the downtown campus was dedicated to Charles E. Daniel in 1965 with a plaque that called him a “man of vision.”

Southern Research Daniel Lab
The Daniel Foundation and Daniel Construction Co. donated funds for the Daniel Laboratory, which opened in 1965.

Since 1978, the Daniel Foundation has supported Southern Research with donations approaching $1.2 million, counting the new gift. The funding has supported the Cancer Cause and Prevention Laboratory, the Engineering Research Center, and Southern Research’s capital needs.

“Southern Research has a long history of positively influencing economic development in our region, and the Daniel Foundation of Alabama has been a valuable partner in our scientific and engineering endeavors for decades,” said Art Tipton, Ph.D., president and CEO.

“The foundation’s latest gift will help power the work of our researchers, who are continuously pursuing leads and making discoveries that add vitality to the region’s economy and enrich lives in Alabama and beyond,” he added.

MAKING CONTRIBUTIONS

Southern Research contributes to Alabama’s strategic economic development growth effort through high-level research, partnerships, talent recruitment, and the commercialization of therapies and technologies.

Its scientists and engineers perform highly skilled technical work that attracts substantial government and commercial research funding from around the world. Agencies within the National Institutes of Health, NASA, and private corporations have all been important sponsors of work conducted at Southern Research.

The organization’s activities with economic development potential include a comprehensive drug discovery program, research into infectious diseases such as the Zika virus, new technology initiatives within the engineering division, exploration of renewable energy storage technologies, and the development of medical devices.

The Daniel Foundation of Alabama is an active member of the state’s philanthropic community, supporting educational, health, humanitarian and cultural activities in Birmingham and throughout Alabama. The foundation has also supported organizations with an economic development and entrepreneurship focus.